medigraphic.com

2011, Number 2

<< Back Next >>

Rev Cuba Endoc 2011; 22 (2)

Insulin resistance and metabolic changes in obese adults

Fernández RR, Arranz CMC, Ortega SJA, Hernández RJ

Language: Spanish
References: 33
Page: 78-90
PDF size: 111.84 Kb.


ABSTRACT

Introduction: the relation obesity-insulin resistance-diabetes mellitus-high blood pressure is more and more significant due to the more relevant role of obesity in the development of each of them. The obese persons are about the 20 to 30 % of Cuban population and this disease or pathologic condition every day is a more important health problem.
Objective: an observational study was conducted in obese adult subjects of both sexes aged between 18 and 60, seen in the National Institute of Endocrinology from 2006 to 2008. In present study also were included those subjects apparently healthy, with a normal height, selected from health institutions of primary care of Plaza municipality. All subjects (N= 214) were classified in 4 groups: body mass index (BMI) between 18,5 and 24,9), pre-obese I (BMI between 25 and 29,9), obese grade II (BMI from 30 to 34,9), obese grade III (BMI between 35 and 39,9). As well as the clinical examination and anthropometric measurements, a fasting blood sample was taught to determine the following serum analytes: glycemia, insulin, to total cholesterol, triglycerides, creatinine and uric acid. Also, the insulin resistance was measured from glycemia and the insulinemia figure according HOMA index.
Results: there was a significant association between abdominal circumference and the body mass index with the insulin resistance rate. Also, this showed a significant correlation (p< 0,05) with the uric acid figure in plasma. It was noted the as the body mass index was greater there were significant increases mean values in glucose plasma, insulin, triglycerides, total cholesterol, creatinine and uric acid.
Conclusion: according to a progression in obesity there are significant metabolic changes in glucidic and lipid metabolism and also in some nitrogenous compounds like the creatinine and uric acid.


REFERENCES

  1. Rossner S. Obesity, the disease of 21th century. Int J Obes. 2002;26(suppl 4):S2-S4.

  2. Mokdad AH, Bowman BA, Ford ES. The continuing epidemic of obesity and diabetes in the United States. JAMA. 2001;286:1995-2000.

  3. Montero JC. Epidemiología de la obesidad en siete países de América Latina. Nutric obes. 2002;5(6):325-30.

  4. Booth ML, Chey T, Wake M, Northon K, Hesketh K, Dallman J, et al. Change in the prevalence of overweight and obesity among young- australians, 1969-1997. Am J Clin Nutr. 2003;77(1):29-36.

  5. Katzmarzyk PT. The Canadian obesity epidemic. CMAJ. 2002;166(8):1985-98.

  6. Barthel B, Cariou C, Lebos-Soison E, Mamos I. Prevalence of obesity in children: study in the primary Parisian schools. Sante Publ. 2001;13(1):7-15.

  7. Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ. Persistence of prediabetes in overweight and obese hispanic children. Association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes. 2008;57:3007-12.

  8. MINSAP. Anuario estadístico del Ministerio de Salud Pública Cuba; 2006. p. 111,25- 6.

  9. Yanes Quesada MA, Yanes Quesada M, Calderín Bouza R, Cruz Hernández J. Síndrome de insulinorresistencia, una amenaza para la salud. Rev Cubana Endocrinol [serie en internet]. 2008 Dic [citado 4 de abril de 2011];19(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532008000300006&lng=es&nrm=iso&tlng=es

  10. Absetz P, Oldenburg B, Hankonen N, Valve R, Heinonen H, Nissinen A, et al. Type 2 Diabetes Prevention in the Real World: Three-year results of the GOAL Lifestyle Implementation Trial. Diabetes Care. 2009;32:1418-20.

  11. Yates T, Khunti K, Bull F, Gorely T, Davies MJ. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia. 2007;50:1116-26.

  12. O'Brien PO, Dixon J. The extent of the problem of obesity. Am J of Surg. 2002;184(6):s4-s8.

  13. Racette SB, Dusinger S, Deusinger RH. Obesity: overview of prevalence, etiology and treatment. Phys Ther. 2003;83:276-88.

  14. Contreras J. La obesidad: una perspectiva sociocultural. Nutric y obes. 2002;11(8):997-1001.

  15. Díaz Sánchez ME. Manual de antropometría para el trabajo de nutrición. Instituto de Nutrición e Higiene de los Alimentos; 1992. p. 13-4.

  16. American Diabetes Association. Standard of Medical Care in Diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.

  17. Schettler G, Nüssel E. Triglycerides liquicolor GPO-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  18. Lópes-Virella M, Stone MF, Ellis S. Cholesterol determinations in HDL separated by three different methods. Clin Chem. 1989;35:1380-5.

  19. Schettler G, Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  20. Tan CE, Ma S, Wai D, Chew SK, Taie ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians. Diabetes Care. 2004;27:1182-6.

  21. Arranz C, González R. Utilización de un método para la separación de la hormona libre y unida en el radioinmunoensayo de insulina. Rev Cubana Invest Biomed. 1988;7(3):150-6.

  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.

  23. Thielmann K. Rangos normales y patológicos. Capítulo 8. En: Manual de metodología de bioquímica clínica. La Habana: Editorial Ciencias Médicas; 1992. p. 94-116.

  24. Arranz Calzado C, González Suárez RM, Álvarez Álvarez A, Rodríguez Pendás B, Reyes Durán A. Criterios de referencia para los indicadores de secreción de insulina y de los parámetros lipídicos en una población mixta hospitalaria. Rev Cubana Endocrinol [serie en internet]. 2010 [citado 4 de abril de 2011];(21)1. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532010000100001&lng=es&nrm=iso&tlng=es

  25. Henny J, Petitclerc C, Fuentes-Arderiu X, Petersen PH, Queralto JM, Schiele F, et al. Need for revisiting the concept of reference values. Clin Chem Lab Med. 2000;38:589-95.

  26. Zimmet P, Alberti G. The metabolic syndrome: progress towards one definition for an epidemic of our time. Nature clinical practice: endocrinology & metabolism. 2008;4:239.

  27. Bonora E, Capaldo B, Perin PC, Del Prato S, De Mattia G, Frittitta L, et al. Group of Italian Scientists of Insulin Resistance (GISIR). Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis. 2008;18(9):624-31.

  28. González R, Perich P, Arranz C. Heterogeneidad de los trastornos metabólicos de las etapas iniciales de la diabetes mellitus 2. Rev Cubana Endocrinol [serie en internet]. 2009 Abr [citado 4 abril 2011];20(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532009000100003&lng=es&nrm=iso&tlng=es

  29. González Suárez RM, Perich Amador P, Arranz Calzado C. Trastornos metabólicos asociados con la evolución hacia la diabetes mellitus tipo 2 en una población en riesgo. Rev Cubana Endocrinol [serie en internet]. 2010 [citado 4 abril 2011];21(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532010000200001&lng=pt&nrm=iso&tlng=es

  30. Williams JW, Zimmet P, Shaw JE, de Courten MP, Cameron AJ, Chitson P, et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20:915-20.

  31. Festa A, Williams K, D'Agostino R, Wagenknecht LE, Haffner S M. The natural course of Beta Cell functions in nondiabetic and diabetic individuals in the Insulin Resistance Atherosclerosis Study (IRAS). The Insulin Resistance Atherosclerosis Study Diabetes. 2006;55:1114-20.

  32. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Diabetes Prevention Program Research Group. Nature Clinical Practice, Endocrinology and Metabolism. 2008;4:382-93.

  33. Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep. 2010 Apr;12(2):113-9.




2020     |     www.medigraphic.com